Product Description
MK-8457 is a novel inhibitor of spleen tyrosine kinase (SYK) and zeta-chain-associated protein kinase 70 (ZAP70) that is being investigated as an RA treatment.Ê (Sourced from: https://acrabstracts.org/abstract/efficacy-and-safety-of-mk-8457-a-novel-syk-inhibitor-for-the-treatment-of-rheumatoid-arthritis-in-two-randomized-controlled-phase-2-studies/)
Mechanisms of Action: SYK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Merck
Company Location: Eastern America
Company Founding Year: 1668
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Arthritis, Rheumatoid
Phase 1: Hypertension
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01446003 |
MK-8457-004-AM1 | P1 |
Completed |
Hypertension |
2012-02-18 |
2022-05-04 |
Primary Endpoints|Treatments |
|
2012-002181-12 |
A Phase IIa POC study to evaluate Safety, Tolerability and Efficacy in Subjects with RA | P2 |
Completed |
Arthritis, Rheumatoid |
2016-10-19 |
2022-03-13 |
Treatments |
|
2012-000439-17 |
Proof-of-Concept of MK-8457 in patients with Rheumatoid Arthritis | P2 |
Terminated |
Arthritis, Rheumatoid |
2014-10-10 |
2022-03-13 |
Treatments |
|
NCT01651936 |
MK-8457-010 | P2 |
Terminated |
Arthritis, Rheumatoid |
2013-10-08 |
2022-05-04 |
Primary Endpoints|Treatments |
|
NCT01569152 |
P08683, MK-8457-008 | P2 |
Terminated |
Arthritis, Rheumatoid |
2013-10-03 |
2022-05-04 |
||
JapicCTI-132235 |
JapicCTI-132235 | P2 |
Terminated |
Arthritis, Rheumatoid |
2013-10-01 |
|||
ACTRN12612000774820 |
ACTRN12612000774820 | P2 |
Terminated |
Arthritis, Rheumatoid |
2013-05-23 |
2024-08-29 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|